Darzalex Solid Tumor And PD-(L)1 Combo Future Dashed

 
• By Eleanor Malone

Hopes for Genmab/Janssen's myeloma drug daratumumab in solid tumors have faded after the CALLISTO trial in combination with Roche's Tecentriq in NSCLC was halted for lack of benefit and increased mortality. The future is dim for Darzalex in combination with PD-(L)1 therapies in general.

ship wrecked
Darzalex has run aground in PD-(L)1 combos and solid tumors • Source: Shutterstock

More from Clinical Trials

More from R&D